Parathyroid cancer is a rare type of cancer that originates from the cells in parathyroid gland. In the United States, there are less than 100 cases per year. Parathyroid cancer can either be sporadic or inherited. Inherited disorders such as Multiple endocrine neoplasia type 1 can also increase the risk of developing parathyroid cancer.
PreSENTIA hereditary Parathyroid cancer panel tests for numerous germline mutations that could cause parathyroid cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
You should get tested if you meet at least one of the criteria below:
• You have a personal or family history of a hereditary cancer syndrome associated with parathyroid cancer
• You have at least two first-degree family members who have had parathyroid tumors
• You have a family member that has been diagnosed with a germline mutation associated with cancer susceptibility
How many genes are tested in this panel?
How many hereditary cancer syndromes are associated with this panel?
1 Hereditary cancer syndrome is associated with this panel. This is:
• Multiple endocrine neoplasia type 1 (MEN1)
References and more information:
• The information above was taken by professional bodies such as NCI
• Wei CH, Harari A. Parathyroid carcinoma: update and guidelines for management. Curr Treat Options Oncol. 2012 Mar;13(1):11-23. doi: 10.1007/s11864-011-0171-3. PMID: 22327883.
• Ullah A, Khan J, Waheed A, Sharma N, Pryor EK, Stumpe TR, Velasquez Zarate L, Cason FD, Kumar S, Misra S, Kavuri S, Mesa H, Roper N, Foroutan S, Karki NR, Del Rivero J, Simonds WF, Karim NA. Parathyroid Carcinoma: Incidence, Survival Analysis, and Management: A Study from the SEER Database and Insights into Future Therapeutic Perspectives. Cancers (Basel). 2022 Mar 10;14(6):1426. doi: 10.3390/cancers14061426. PMID: 35326576; PMCID: PMC8946517.